



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	309065	Calcium K2 with D3
ARTG entry for	Medicine Listed	
Sponsor	Herbs of Gold Pty Ltd	
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
ARTG Start Date	7/09/2018	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Calcium K2 with D3

Product Type	Single Medicine Product	Effective Date	16/11/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support healthy teeth
Maintain/support teeth mineralisation
Maintain/support bone health
Maintain/support bone health in post-menopausal women
Maintain/support bone mass/density/integrity
Maintain/support bone mass/density/integrity in post-menopausal women
Maintain/support (state mineral) absorption in bones
Maintain/support bone strength
Maintain/support bone strength in post-menopausal women
Help maintain/support bone mineralisation
A diet deficient in calcium can lead to osteoporosis in later life. Calcium may help prevent osteoporosis when dietary intake is inadequate
Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Indication can only be used for medicines that contain calcium as an active ingredient and the recommended daily dose of the medicine must provide at least 290 milligrams of elemental calcium.

Standard Indications

No Standard Indications included on Record

Specific Indications



Australian Government
Department of Health
Therapeutic Goods Administration

No Specific Indications included on Record

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

calcified lithothamnion tophiforme	395.8365 mg
calcium citrate tetrahydrate	611.4 mg
Equivalent: calcium	125 mg
colecalfiferol	.0083 mg
menaquinone 7	.015 mg

Other Ingredients (Excipients)

Acacia
calcium phosphate
croscarmellose sodium
dl-alpha-tocopherol
lecithin
macrogol 3000
magnesium stearate
maize starch
medium chain triglycerides
microcrystalline cellulose
polyvinyl alcohol
povidone
purified talc
silicon dioxide
sodium ascorbate
starch sodium octenyl succinate
sucrose
titanium dioxide

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.